ClinicalTrials.gg
CompletedNCT02212886Updated Nov 16, 2026

Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS

A Phase 1/2 interventional study of GA Depot 80 mg and GA Depot 40 mg in Multiple Sclerosis, sponsored by Mapi Pharma Ltd.. Completed at 3 sites in Israel. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Primary conditionMultiple Sclerosis, Relapsing-RemittingRegistry: Multiple SclerosisReclassifiedWhy we changed it
Registry
Multiple Sclerosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Sclerosis, Relapsing-Remitting
Why
  1. The study's title name Multiple Sclerosis, Relapsing-Remitting, a narrower term within Multiple Sclerosis.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Mapi Pharma Ltd. · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 16, 2026Primary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Multiple Sclerosis, Relapsing-Remitting with a site in Israel — none open to participants now, 1 under way, 1 of them phase 3. Multiple Sclerosis, Relapsing-Remitting · Israel.

Enrollment
24th of 25
25 · median 1,062
Started
2014
with 1 other
Phase 1/2
Only one
of the 27
Registered
22nd of 27
by date
Lead sponsor
2 of 27
Mapi Pharma Ltd.

Among the 27 studies in Multiple Sclerosis, Relapsing-Remitting with a site in Israel, this one is the 24th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2014, is the only one in phase 1/2, and was the 22nd registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 27 studies in Multiple Sclerosis, Relapsing-Remitting with a site in Israel is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 27 studies in Multiple Sclerosis, Relapsing-Remitting with a site in Israel as a file.
02

Study summary

  • This is a phase IIa study in which GA Depot 80 or 40mg is administered as an IM injection to subjects with RRMS at 4 week intervals for 52 weeks of treatment.
  • The purpose of the study is to assess safety, tolerability, and efficacy of a monthly long-acting IM injection of 80 or 40mg GA Depot in subjects with RRMS. The study will include subjects switching from daily or thrice weekly administration of 20 mg or 40mg respectively of glatiramer acetate (GA, i.e., Copaxone®) injection
Read the detailed description
  • 25 Subjects with a diagnosis of relapsing remitting multiple sclerosis (RRMS) who are treated with daily or thrice weekly subcutaneous injections of 20 mg or 40 mg respectively of GA (Copaxone®) during the previous 12 months
  • Study product is GA long-acting injection (GA Depot) which is a combination of extended-release microspheres for injection and diluent (water for injection) for parenteral use. GA Depot will be administered intramuscularly (IM).
  • The study duration for an individual subject in the core study will be 60 weeks, consisting of 4 weeks of screening evaluation (weeks -4 to 0), followed by a 52-week open-label treatment period, and a 4 weeks follow up period: through a total of 17 visits.
  • For both arms, subjects who completed 13 injections and who consented (by signing an informed consent) are able to enter the optional 8 years extension period. During the extension period subjects will receive 40 mg of GA Depot IM once every 4 weeks.
  • Physical, vital signs and safety assessment - will be performed at each visit during the whole study. Physical examination will be performed quarterly during the extension period.
  • MRI at visit 1 (screenings), at week 24, week 52 (end of core study) and every 6 months during the extension period.
  • Neurological and safety laboratory tests at screening visit, on visits in weeks 4, 12, 24, 36, 52 (end of core study) and every 6 months during the extension period.
03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Glatiramer acetate
  • Copaxone®
  • Multiple sclerosis
  • Relapsing remitting multiple sclerosis
  • RRMS
  • GA Depot
  • Monthly injection
04

In context

Multiple Sclerosis, Relapsing-Remitting Reclassified

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

This study's enrollment of 25 is below the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Lead sponsor

Mapi Pharma Ltd. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Compared within Multiple Sclerosis, Relapsing-Remitting, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Multiple Sclerosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects with a diagnosis of RRMS.
  • Diagnosis of multiple sclerosis (MS) consistent with the McDonald Criteria (revisions of 2010).
  • Treatment with 20 mg or 40 mg of GA (Copaxone®) during the previous 12 months with ongoing treatment at the Screening Visit.
  • Normal renal function.
  • Normal liver function.
  • Normal concentration.
  • Absence of any medical, psychiatric or laboratory abnormalities.
  • Ability to provide written .

Exclusion criteria

Exclusion Criteria:

  • Any relevant medical, surgical, or psychiatric condition, laboratory value, or concomitant medication which, in the opinion of the investigator, makes the subject unsuitable for study entry or potentially unable to complete all aspects of the study.
  • Concomitant disease.
  • Severe anemia ( \< 10 g/dL).
  • Abnormal renal function (serum creatinine > 1.5xULN).
  • Abnormal liver function (transaminases >2xULN).
  • Pregnant or breast-feeding women.
  • Women capable of child bearing must have a negative urine pregnancy test at screening visit and use an adequate method throughout the study. Women who are surgically sterile (hysterectomy or tubal ligation) or whose last menstruation was 12 months or more prior to the Screening Visit are considered to be of non-. Acceptable forms of contraception include oral, implanted, or injected contraceptives; intrauterine devices in place for at least 3 months; estrogen patch; and adequate barrier methods in conjunction with spermicide. Abstinence is considered an acceptable contraceptive regimen.
  • History of any anaphylactic reaction and/or serious allergic reaction following a vaccination, a proven to any component of the study drug, e.g. GA, polylactic-co-glycolic acid (PLGA), polyvinyl alcohol (PVA).
  • Known or suspected history of drug or alcohol abuse.
  • Positive test for , hepatitis, venereal disease research laboratory test (VDRL), or tuberculosis.
  • Participation in an drug study within 30 days prior to start of this study.
  • Active malignant disease of any kind. However, a patient, who has had a malignant disease in the past, was treated and is currently disease - free for at least 5 years, may be considered to be enrolled in the study. In this case the sponsor medical expert approval is required.
  • Treatment with any kind of during the last 30 days.
  • Confirmed relapse during the last 30 days.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    GA Depot 80mg

    Monthly IM injection

    Drug: GA Depot 80 mg

  • Experimental
    GA Depot 40mg

    Monthly IM injection

    Drug: GA Depot 40 mg

Interventions

  • DrugGA Depot 80 mg

    Recruitment completed

    Also known as: Microspheres containing GA

  • DrugGA Depot 40 mg

    Recruitment completed

    Also known as: Microspheres containing GA

07

What researchers measure

Primary outcomes

  1. Safety / Adverse events

    Number of patients experiencing adverse events and assessments of localized skin reactions at injection sites.

    Time frame: During the study

Secondary outcomes

  1. Efficacy/Change in Relapse Rate

    Annualized Relapse Rate (ARR) detected during the study.

    Time frame: During the study

  2. Efficacy/Changes in brain MRI

    Changes from baseline to end of treatment visit in the number of enhancing lesions and new lesions images of brain MRI.

    Time frame: During the study (1 year treatment)

  3. Efficacy/Changes in EDSS

    Change from baseline to end of treatment visit of Expanded Disability Status Scale (EDSS) score.

    Time frame: During the study

08

Study locations

3 sites
  • Barzilai Medical Center
    Ashkelon, Israel
  • Rambam Medical Center
    Haifa, Israel
  • TASMC
    Tel Aviv, Israel
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2014 to primary completion in May 2017, 31 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2014
First posted
Aug 8, 2014
StartActual
Oct 2014
Primary completionActual
May 2017
CompletionActual
Nov 20, 2024
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameSafety / Adverse eventsDuring the study (1 year treatment) → During the study
Nov 16, 2026
Secondary outcomes
2 time frame changed, 2 description edited
What changed in the outcomes
  • Time frameEfficacy/Change in Relapse RateDuring the study (1 year treatment) → During the study
  • Time frameEfficacy/Changes in EDSS1 year → During the study
  • DescriptionEfficacy/Change in Relapse Rate: how it is measured was reworded
  • DescriptionEfficacy/Changes in brain MRI: how it is measured was reworded
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameSafety / Adverse eventsDuring the study (1 year treatment) → During the study
    Secondary outcomes 2 time frame changed, 2 description edited
    What changed in the outcomes
    • Time frameEfficacy/Change in Relapse RateDuring the study (1 year treatment) → During the study
    • Time frameEfficacy/Changes in EDSS1 year → During the study
    • DescriptionEfficacy/Change in Relapse Rate: how it is measured was reworded
    • DescriptionEfficacy/Changes in brain MRI: how it is measured was reworded
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02212886
Lead sponsor
Mapi Pharma Ltd.
Responsible party
Sponsor
First posted
Aug 8, 2014
Start date
Oct 2014
Primary completion
May 2017
Completion
Nov 20, 2024
Last update
Nov 16, 2026

Study contacts

Shlomo Flechter, M.D
principal investigator

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion